Copyright
©The Author(s) 2024.
World J Clin Oncol. Oct 24, 2024; 15(10): 1293-1308
Published online Oct 24, 2024. doi: 10.5306/wjco.v15.i10.1293
Published online Oct 24, 2024. doi: 10.5306/wjco.v15.i10.1293
Group | 24 hours OD | Proliferation rate (%) | 48 hours OD | Proliferation rate (%) |
Control | 1.88 ± 0.02 | 2.73 ± 0.04 | ||
10% BXD | 1.85 ± 0.01 | 98 | 2.36 ± 0.06b | 86.09 |
20% BXD | 0.91 ± 0.07b | 45.78 | 1.53 ± 0.02b | 54.62 |
40% BXD | 0.48 ± 0.01b | 21.18 | 0.54 ± 0.02b | 17.09 |
Capecitabine | 1.00 ± 0.06b | 50.48 | 1.65 ± 0.19b | 59.11 |
LY294002 | 1.00 ± 0.01b | 50.25 | 1.00 ± 0.07b | 34.7 |
BXD + LY294002 | 0.64 ± 0.04b | 30.07 | 0.77 ± 0.05b | 26.05 |
- Citation: Zu GX, Sun KY, Liu XJ, Tang JQ, Huang HL, Han T. Banxia xiexin decoction prevents the development of gastric cancer. World J Clin Oncol 2024; 15(10): 1293-1308
- URL: https://www.wjgnet.com/2218-4333/full/v15/i10/1293.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i10.1293